Age-related macular degeneration (AMD) is an eye disease that affects central vision. Hyperbaric oxygen therapy (HBOT) increases oxygen availability in the body by delivering oxygen under elevated pressure. Researchers have explored whether this may influence retinal function in people with AMD. However, current evidence is limited to small clinical studies and case reports. HBOT is not an established standard treatment for AMD and has not been proven to slow disease progression or preserve vision.
Key Takeaways
- AMD affects central vision and occurs in dry and wet forms.
- HBOT increases oxygen availability, but its clinical benefits for AMD remain uncertain.
- Established AMD management includes anti-VEGF injections for wet AMD and AREDS2 supplements for eligible patients.
- HBOT should not replace ophthalmologic care or prescribed treatment.
1. What Is Age-Related Macular Degeneration (AMD)?
Age-related macular degeneration is a progressive eye disease that affects the macula, the central part of the retina responsible for detailed vision. It can make reading, recognizing faces, and performing other everyday activities more difficult.
AMD generally occurs in two forms.
Dry AMD is associated with changes in the retinal pigment epithelium and the accumulation of deposits called drusen. As the disease progresses, retinal tissue may deteriorate, potentially leading to significant central vision loss.
Wet AMD develops when abnormal blood vessels grow beneath or around the retina and leak fluid or blood. It can cause more rapid changes in vision and requires prompt ophthalmologic assessment.
Age is a major risk factor. Smoking, genetics, and other health-related factors can also influence disease risk. Because AMD has different stages and forms, appropriate management depends on an accurate diagnosis and regular retinal monitoring.
2. Why Oxygen Matters to Retinal Health
The retina has high metabolic demands and requires a continuous supply of oxygen to support the activity of its light-sensitive cells and other retinal structures. Oxygen delivery depends on blood circulation, tissue metabolism, and the interaction between different layers of the retina.
These relationships have attracted interest in hyperbaric oxygen therapy. Under elevated pressure, breathing oxygen increases the amount dissolved in blood plasma, potentially changing oxygen delivery to certain tissues.
However, retinal health is not simply a matter of increasing oxygen supply. Oxygen also participates in the formation of reactive oxygen species, which can contribute to oxidative stress when cellular antioxidant defenses are insufficient. Oxidative stress is one of several biological processes implicated in retinal aging and AMD.
Therefore, the relationship between oxygen and retinal function is complex. Although oxygen availability is essential for normal cellular activity, it does not follow that additional oxygen will improve AMD outcomes. Whether HBOT can provide a meaningful benefit without introducing additional risks remains an important research question.
3. What Does Research Say About HBOT for AMD?
Potential Mechanisms
Researchers have proposed that increased oxygen availability could influence retinal metabolism and the function of tissues involved in vision. HBOT may alter oxygen delivery under specific physiological conditions, providing a possible basis for investigating its effects on retinal function.
These mechanisms remain hypotheses when applied to AMD treatment. They do not establish that HBOT can repair damaged retinal cells, reverse macular degeneration, or prevent the development of abnormal blood vessels.
It is also important not to assume that HBOT suppresses vascular endothelial growth factor (VEGF) or reduces the need for anti-VEGF injections. These outcomes have not been established for HBOT in AMD.
Clinical Evidence and Vision Outcomes
A 2010 report published in Undersea & Hyperbaric Medicine described 14 patients with advanced AMD who received HBOT. The treatment involved one-hour sessions at either 1.5 or 1.75 atmospheres absolute (ATA). The authors reported improvements in visual acuity, visual fields, or activities of daily living in some patients. Read the study on PubMed.
Although these observations are noteworthy, the study was small and did not establish that HBOT caused the reported improvements. Without an appropriate control group, it is difficult to distinguish treatment effects from measurement variability, changes in patient performance, or other influences.
The study also does not establish whether any improvements were sustained over the long term or whether HBOT can slow the underlying progression of AMD.
Larger, well-controlled clinical trials are needed to evaluate visual acuity, retinal structure, functional outcomes, long-term safety, and differences between dry and wet AMD. At present, there is insufficient evidence to recommend HBOT as a routine treatment for either form of the disease.
4. HBOT Protocols for Macular Degeneration
No standardized, evidence-based HBOT protocol has been established for AMD. The pressure levels used in individual reports should not be interpreted as recommended treatment settings.
Research protocols may differ in treatment pressure, session duration, treatment frequency, and total number of sessions. Researchers must also consider how outcomes are measured and whether potential benefits persist after treatment ends.
If HBOT is being considered in a research setting, assessment by a retinal specialist and a qualified hyperbaric medicine professional is essential. Baseline visual acuity, retinal imaging, disease stage, and relevant medical history may all be important.
Patients should not independently adopt treatment schedules used for other medical conditions or purchase a chamber based on an unverified AMD protocol.
5. Safety Considerations and Standard AMD Treatment
HBOT has recognized risks, including ear and sinus pressure injuries, temporary vision changes, and, rarely, oxygen toxicity. Because AMD affects delicate retinal structures, potential effects on ocular oxygen balance require careful consideration. The safety and effectiveness of repeated HBOT sessions specifically for AMD have not been adequately established.
Established AMD management should remain the priority.
For wet AMD, anti-VEGF injections administered by an ophthalmologist are a principal treatment. These medicines target abnormal blood vessel activity and can help stabilize or improve vision in many patients.
For eligible patients with intermediate AMD or certain stages of advanced AMD, AREDS2 nutritional supplements may help reduce the risk of progression to more advanced disease. They are not appropriate for every stage or every patient, so an eye care professional should determine whether supplementation is suitable.
Regular retinal examinations, appropriate imaging, smoking cessation, and a balanced diet also contribute to AMD management. New distortion, a sudden change in central vision, or newly appearing blind spots warrant urgent ophthalmologic assessment.
6. Can a Home Hyperbaric Chamber Be Used for AMD?
Home hyperbaric chambers may interest people seeking convenient access to pressurized oxygen environments. However, convenience does not establish medical suitability, and a home chamber should not automatically be considered equivalent to a clinical HBOT facility.
When evaluating equipment, buyers should consider operating pressure, oxygen delivery, safety systems, manufacturer instructions, and the level of professional support available. Soft-shell and hard-shell chambers can differ in pressure capabilities, design, and intended use.
Higher operating pressure does not prove greater effectiveness for AMD. No home chamber has been established as a proven treatment for preventing AMD progression or preserving vision.
For manufacturers and distributors, responsible product communication is particularly important in this area. Product specifications and intended uses should be presented accurately, without promising vision improvement or suggesting that HBOT can replace retinal treatment.
Anyone with AMD who is considering home HBOT should consult a retinal specialist before proceeding. A purchase decision should not be based on unverified treatment claims or protocols developed for unrelated conditions.
Conclusion
HBOT increases oxygen availability and provides a scientific basis for investigating possible effects on retinal function. However, current evidence for treating age-related macular degeneration remains insufficient, and improvements in vision or disease progression have not been established through robust clinical trials.
Patients should prioritize evidence-based ophthalmologic care and discuss experimental approaches with a retinal specialist. Further controlled research is needed before HBOT can be considered an effective and appropriate option for AMD.
